Warning: Use of undefined constant php - assumed 'php' (this will throw an Error in a future version of PHP) in /var/www/pregnancylab/data/www/pregnancylab.net/wp-content/themes/twentytwelve/content-page.php on line 14

Our Research

Ectopic Pregnancy

  1. Human chorionic gonadotropin discriminatory zone in ectopic pregnancy: does assay harmonization matter?
  2. Circulating microRNA miR-323-3p as a biomarker of ectopic pregnancy
  3. Serum activin A does not predict ectopic pregnancy as a single measurement test, alone or as part of a multi-marker panel including progesterone and hCG

Fetal Lung Maturity

  1. Fetal lung maturity testing: the end of an era
  2. Predicting respiratory distress syndrome using gestational age and lamellar body count
  3. Discrepancy in lamellar body counts (LBCs) between the Sysmex XE-2100 and Sysmex XT-2000i instruments
  4. Validation of lamellar body counts using three hematology analyzers
  5. Clinical and laboratory trends in fetal lung maturity testing
  6. Biomarker tests for fetal lung maturity
  7. Validation of the L/S ratio determined by digital scanning densitometry
  8. Fetal lung maturity
  9. A direct comparison between lamellar body counts and fluorescent polarization methods for predicting respiratory distress syndrome
  10. The mean weekly increment of amniotic fluid TDx-FLM II ratio is constant during the latter part of pregnancy
  11. Predicting respiratory distress syndrome using gestational age and fetal lung maturity by fluorescent polarization
  12. Preanalytical factors that influence the Abbott TDx Fetal Lung Maturity II assay
  13. Prediction of risk for respiratory distress syndrome using gestational age and the TDx-FLM II assay
  14. Lamellar body count in amniotic fluid: a comparative study of four different hematology analyzers
  15. Bilirubin in amniotic fluid does not interfere with the Abbott TDx FLM II assay
  16. Assessment of the diagnostic accuracy of the TDx-FLM II to predict fetal lung maturity
  1. Establishing reference intervals for hCG in postmenopausal women.
  2. Inappropriate Off-label Use of a Qualitative, Point-of-care hCG Device.
  3. Characterizing urinary hCGβcf patterns during pregnancy.
  4. Heterophile antibody interference in qualitative urine/serum hCG devices: Case report.
  5. Estimating the hCGβcf in urine during pregnancy.
  6. Pathology consultation on human chorionic gonadotropin testing for pregnancy assessment.
  7. Evaluation of a semi-quantitative pregnancy device for susceptibility to interference caused by hCGβcf.
  8. Analytical performance evaluation of the i-STAT Total β-human chorionic gonadotropin immunoassay.
  9. Assessing the risk of false negative point-of-care urinary human chorionic gonadotropin device results due to beta core fragment.
  10. Variable accuracy of home pregnancy tests: truth in advertising?
  11. Performance characteristics of the Beckman Coulter total βhCG (5th IS) assay.
  12. Qualitative Point-of-Care Human Chorionic Gonadotropin Testing: Can We Defuse This Ticking Time Bomb?
  13. Improved Performance of Point-of-Care and Over-the-Counter Qualitative Human Chorionic Gonadotropin Measurement Devices
  14. Screening method to evaluate point-of-care human chorionic gonadotropin (hCG) devices for susceptibility to the hook effect by hCG β core fragment: evaluation of 11 devices
  15. Evaluation of leukocyte and bacterial interference in point-of-care human chorionic gonadotropin tests
  16. Point-of-care and over-the-counter qualitative human chorionic gonadotropin (hCG) devices remain susceptible to false-negative results caused by excess hCG β core fragment
  17. Inappropriate use of qualitative, point-of-care urine human chorionic gonadotropin test
  18. Analytical and clinical validation of the Immulite 1000 hCG assay for quantitative analysis in urine
  19. Limitations in qualitative point of care hCG tests for detecting early pregnancy
  20. Should the qualitative serum pregnancy test be considered obsolete?
  21. Falsely decreased human chorionic gonadotropin (hCG) results due to increased concentrations of the free beta subunit and the beta core fragment in quantitative hCG assays
  22. An unlikely pregnancy
  23. The analytical specificity of human chorionic gonadotropin assays determined using WHO International Reference Reagents
  24. Qualitative point-of-care and over-the-counter urine hCG devices differentially detect the hCG variants of early pregnancy
  25. Characterization of the hCG variants recognized by different hCG immunoassays: an important step toward standardization of hCG measurements
  26. Serum human chorionic gonadotropin concentrations greater than 400,000 IU/L are invariably associated with suppressed serum thyrotropin concentrations
  27. Clinical assays for human chorionic gonadotropin: what should we measure and how?
  28. False-negative results from point-of-care qualitative human chorionic gonadotropin (hCG) devices caused by excess hCGbeta core fragment vary with device lot number
  29. False-negative results in point-of-care qualitative human chorionic gonadotropin (hCG) devices due to excess hCGbeta core fragment
  30. Use of serum FSH to identify perimenopausal women with pituitary hCG
  31. Method validation for cerebral spinal fluid human chorionic gonadotropin measurement with the Advia Centaur
  32. Detection of unexpected isoforms of human chorionic gonadotropin by qualitative tests
  33. Persistent low concentration of human chorionic gonadotropin in a nonpregnant woman
  34. Diagnostic considerations in the measurement of human chorionic gonadotropin in aging women
  35. Endometrial adenocarcinoma associated with elevated serum concentrations of the free beta subunit of human chorionic gonadotropin
  36. Method evaluation for total beta-human chorionic gonadotropin using urine and the ADVIA Centaur
  37. Total beta-human chorionic gonadotropin measured in urine by an automated method

Hemolytic Disease of the Newborn

  1. Comparison of various methods for amniotic fluid delta OD450 bilirubin measurement
  2. Effect of blood contamination on delta 450 bilirubin measurement: an in vitro comparison of two corrective methods

Non-invasive Prenatal Testing

  1. A cost-effectiveness analysis of first trimester non-invasive prenatal screening for fetal trisomies in the United States.
  2. Non-invasive prenatal testing using cell-free fetal DNA in maternal circulation


  1. The relationship between PTH and 25-hydroxy vitamin D early in pregnancy


  1. False-positive results in home ovulation prediction devices due to very low concentrations of human chorionic gonadotropin

Preterm Delivery

  1. Cervicovaginal interleukin-6 as a predictor of preterm birth in African American women
  2. Diagnostic accuracy of cervicovaginal interleukin-6 and interleukin-6:albumin ratio as markers of preterm delivery
  3. Cervicovaginal interleukin-6, tumor necrosis factor-alpha, and interleukin-2 receptor as markers of preterm delivery
  4. Accuracy of the rapid fetal fibronectin TLi system in predicting preterm delivery

Thyroid Disorders

  1. Evaluation of thyroid function during pregnancy: have we taken a wrong turn?
  2. Establishment of reference intervals for thyroid-stimulating hormone and free thyroxine in amniotic fluid using the Bayer ADVIA Centaur
  3. Establishment of reference intervals for markers of fetal thyroid status in amniotic fluid
  4. Thyroid function during pregnancy
  5. Serum human chorionic gonadotropin concentrations greater than 400,000 IU/L are invariably associated with suppressed serum thyrotropin concentrations
(Visited 62 times, 1 visits today)